ALNY vs. RARE: A Head-to-Head Stock Comparison

Updated on August 23, 2025

Here’s a clear look at ALNY and RARE, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.

Company Profile

Symbol	ALNY	RARE
Company Name	Alnylam Pharmaceuticals, Inc.	Ultragenyx Pharmaceutical Inc.
Country	United States	United States
GICS Sector	Health Care	Health Care
GICS Industry	Biotechnology	Biotechnology
Market Capitalization	60.07 billion USD	2.83 billion USD
Exchange	NasdaqGS	NasdaqGS
Listing Date	June 1, 2004	January 31, 2014
Security Type	Common Stock	Common Stock

Historical Performance

This chart compares the performance of ALNY and RARE by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.

ALNY vs. RARE: Growth of a $10,000 investment over the past one year.

Historical Performance at a Glance

Symbol	ALNY	RARE
5-Day Price Return	3.52%	1.21%
13-Week Price Return	57.03%	-18.87%
26-Week Price Return	73.02%	-32.54%
52-Week Price Return	66.97%	-45.41%
Month-to-Date Return	16.84%	7.47%
Year-to-Date Return	94.77%	-30.21%
10-Day Avg. Volume	1.28M	1.48M
3-Month Avg. Volume	1.04M	1.63M
3-Month Volatility	38.50%	65.33%
Beta	0.33	0.18

Profitability

Return on Equity (TTM)

ALNY

-274.21%

Biotechnology Industry

Max: 77.14%
Q3: 10.76%
Median: -20.08%
Q1: -42.71%
Min: -119.20%

ALNY has a negative Return on Equity of -274.21%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.

RARE

-237.48%

Biotechnology Industry

Max: 77.14%
Q3: 10.76%
Median: -20.08%
Q1: -42.71%
Min: -119.20%

RARE has a negative Return on Equity of -237.48%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.

ALNY vs. RARE: A comparison of their Return on Equity (TTM) against the Biotechnology industry benchmark.

Net Profit Margin (TTM)

ALNY

-12.96%

Biotechnology Industry

Max: 59.44%
Q3: 16.21%
Median: -11.49%
Q1: -167.42%
Min: -409.07%

ALNY has a negative Net Profit Margin of -12.96%, indicating the company is operating at a net loss as its expenses exceeded its revenues.

RARE

-87.34%

Biotechnology Industry

Max: 59.44%
Q3: 16.21%
Median: -11.49%
Q1: -167.42%
Min: -409.07%

RARE has a negative Net Profit Margin of -87.34%, indicating the company is operating at a net loss as its expenses exceeded its revenues.

ALNY vs. RARE: A comparison of their Net Profit Margin (TTM) against the Biotechnology industry benchmark.

Operating Profit Margin (TTM)

ALNY

-7.32%

Biotechnology Industry

Max: 60.62%
Q3: 20.76%
Median: -12.41%
Q1: -181.14%
Min: -482.02%

ALNY has a negative Operating Profit Margin of -7.32%. This signifies the company is unprofitable at the operational level, as its core business expenses exceed its revenue.

RARE

-82.78%

Biotechnology Industry

Max: 60.62%
Q3: 20.76%
Median: -12.41%
Q1: -181.14%
Min: -482.02%

RARE has a negative Operating Profit Margin of -82.78%. This signifies the company is unprofitable at the operational level, as its core business expenses exceed its revenue.

ALNY vs. RARE: A comparison of their Operating Profit Margin (TTM) against the Biotechnology industry benchmark.

Profitability at a Glance

Symbol	ALNY	RARE
Return on Equity (TTM)	-274.21%	-237.48%
Return on Assets (TTM)	-7.41%	-37.66%
Net Profit Margin (TTM)	-12.96%	-87.34%
Operating Profit Margin (TTM)	-7.32%	-82.78%
Gross Profit Margin (TTM)	83.64%	85.32%

Financial Strength

Current Ratio (MRQ)

ALNY

2.80

Biotechnology Industry

Max: 19.31
Q3: 9.38
Median: 4.54
Q1: 2.45
Min: 0.76

ALNY’s Current Ratio of 2.80 aligns with the median group of the Biotechnology industry, indicating that its short-term liquidity is in line with its sector peers.

RARE

2.45

Biotechnology Industry

Max: 19.31
Q3: 9.38
Median: 4.54
Q1: 2.45
Min: 0.76

RARE’s Current Ratio of 2.45 aligns with the median group of the Biotechnology industry, indicating that its short-term liquidity is in line with its sector peers.

ALNY vs. RARE: A comparison of their Current Ratio (MRQ) against the Biotechnology industry benchmark.

Debt-to-Equity Ratio (MRQ)

ALNY

4.10

Biotechnology Industry

Max: 1.35
Q3: 0.64
Median: 0.09
Q1: 0.00
Min: 0.00

With a Debt-to-Equity Ratio of 4.10, ALNY operates with exceptionally high leverage compared to the Biotechnology industry norm. This suggests an aggressive reliance on debt financing, which can magnify returns but also significantly elevates financial risk.

RARE

0.00

Biotechnology Industry

Max: 1.35
Q3: 0.64
Median: 0.09
Q1: 0.00
Min: 0.00

RARE’s Debt-to-Equity Ratio of 0.00 is typical for the Biotechnology industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.

ALNY vs. RARE: A comparison of their Debt-to-Equity Ratio (MRQ) against the Biotechnology industry benchmark.

Interest Coverage Ratio (TTM)

ALNY

-0.95

Biotechnology Industry

Max: 72.37
Q3: 1.91
Median: -7.81
Q1: -63.90
Min: -153.80

ALNY has a negative Interest Coverage Ratio of -0.95. This indicates that its earnings were insufficient to cover even its operational costs, let alone its interest payments, signaling significant financial distress.

RARE

-84.57

Biotechnology Industry

Max: 72.37
Q3: 1.91
Median: -7.81
Q1: -63.90
Min: -153.80

RARE has a negative Interest Coverage Ratio of -84.57. This indicates that its earnings were insufficient to cover even its operational costs, let alone its interest payments, signaling significant financial distress.

ALNY vs. RARE: A comparison of their Interest Coverage Ratio (TTM) against the Biotechnology industry benchmark.

Financial Strength at a Glance

Symbol	ALNY	RARE
Current Ratio (MRQ)	2.80	2.45
Quick Ratio (MRQ)	2.63	2.12
Debt-to-Equity Ratio (MRQ)	4.10	0.00
Interest Coverage Ratio (TTM)	-0.95	-84.57

Growth

Revenue Growth

ALNY vs. RARE: A side-by-side comparison of their Revenue Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

EPS Growth

ALNY vs. RARE: A side-by-side comparison of their EPS Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

Dividend

Dividend Yield (TTM)

ALNY

0.00%

Biotechnology Industry

Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

ALNY currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.

RARE

0.00%

Biotechnology Industry

Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

RARE currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.

ALNY vs. RARE: A comparison of their Dividend Yield (TTM) against the Biotechnology industry benchmark.

Dividend Payout Ratio (TTM)

ALNY

0.00%

Biotechnology Industry

Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

ALNY has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.

RARE

0.00%

Biotechnology Industry

Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

RARE has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.

ALNY vs. RARE: A comparison of their Dividend Payout Ratio (TTM) against the Biotechnology industry benchmark.

Dividend at a Glance

Symbol	ALNY	RARE
Dividend Yield (TTM)	0.00%	0.00%
Dividend Payout Ratio (TTM)	0.00%	0.00%

Valuation

Price-to-Earnings Ratio (TTM)

ALNY

Biotechnology Industry

Max: 60.14
Q3: 38.17
Median: 29.01
Q1: 15.12
Min: 0.00

P/E Ratio data for ALNY is currently unavailable.

RARE

Biotechnology Industry

Max: 60.14
Q3: 38.17
Median: 29.01
Q1: 15.12
Min: 0.00

P/E Ratio data for RARE is currently unavailable.

ALNY vs. RARE: A comparison of their Price-to-Earnings Ratio (TTM) against the Biotechnology industry benchmark.

Price-to-Sales Ratio (TTM)

ALNY

24.45

Biotechnology Industry

Max: 76.98
Q3: 36.53
Median: 9.49
Q1: 4.49
Min: 0.00

ALNY’s P/S Ratio of 24.45 aligns with the market consensus for the Biotechnology industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.

RARE

4.60

Biotechnology Industry

Max: 76.98
Q3: 36.53
Median: 9.49
Q1: 4.49
Min: 0.00

RARE’s P/S Ratio of 4.60 aligns with the market consensus for the Biotechnology industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.

ALNY vs. RARE: A comparison of their Price-to-Sales Ratio (TTM) against the Biotechnology industry benchmark.

Price-to-Book Ratio (MRQ)

ALNY

169.67

Biotechnology Industry

Max: 20.53
Q3: 9.76
Median: 4.77
Q1: 2.49
Min: 0.59

At 169.67, ALNY’s P/B Ratio is at an extreme premium to the Biotechnology industry. This signifies that the market’s valuation is heavily reliant on future potential rather than its current net asset value, which can be a high-risk proposition.

RARE

22.72

Biotechnology Industry

Max: 20.53
Q3: 9.76
Median: 4.77
Q1: 2.49
Min: 0.59

At 22.72, RARE’s P/B Ratio is at an extreme premium to the Biotechnology industry. This signifies that the market’s valuation is heavily reliant on future potential rather than its current net asset value, which can be a high-risk proposition.

ALNY vs. RARE: A comparison of their Price-to-Book Ratio (MRQ) against the Biotechnology industry benchmark.

Valuation at a Glance

Symbol	ALNY	RARE
Price-to-Earnings Ratio (TTM)	--	--
Price-to-Sales Ratio (TTM)	24.45	4.60
Price-to-Book Ratio (MRQ)	169.67	22.72
Price-to-Free Cash Flow Ratio (TTM)	336.34	--